To confirm that the anti-leukemia activity of our differentiated NK-like cells was mediated via the activation of NK cell receptors, we evaluated the expression of CD158, CD161 and Nkp30 in NK-like cells upon tumor exposure, as depicted in Fig. 6b. This evidence concerns the gene NCR3 and leukemia.